Kexing Bio, which earns 95.5 billion yuan a year, has a profit of more than 5 Baidu; China Stomatological Medical Has six times entered the Hong Kong Stock Exchange

Photo/unsplash

market

After repeated defeats, China Oral Medicine sprinted to the Hong Kong Stock Exchange for the sixth time

China Stomatological Medical Group Limited (hereinafter referred to as "China Stomatological Healthcare") submitted its listing application on the Hong Kong Stock Exchange again on 29 April 2022, marking its sixth submission.

According to the Hong Kong Stock Exchange, China Dental Healthcare submitted a listing application to the main board of the Hong Kong Stock Exchange, with Chuangsheng Capital and Guojin Securities (Hong Kong) Limited as joint sponsors.

China Stomatological Medical has submitted prospectuses on the Hong Kong Stock Exchange five times on February 10, 2020, August 11, 2020, February 26, 2021 and March 2022, all five times of submission of prospectuses on the Hong Kong Stock Exchange.

According to the Frost & Sullivan Report, China Stomatology is the largest private dental service provider in Wenzhou in terms of revenue in 2020, with a market share of about 23.8% in the private and overall dental service market in Wenzhou (exceeding the total market share of the second to fifth largest private dental service providers in Wenzhou in 2020) and 12.3% respectively.

Since 2011, China Stomatology has provided dental services to individuals of all ages. The benefits are mainly derived from the provision of comprehensive dental services to individuals, mainly covering four dental areas: integrated oral therapy, prosthodontics, implant dentistry and orthodontics.

For the three years ended December 31, 2021, the Company's revenue from dental services was approximately $83.2 million, $84.6 million and $105 million, respectively.

Net income of 95.5 billion yuan, on the profit of Kexing Bio more than 5 Baidu

The 2021 annual report submitted by Kexing Bio is very eye-catching. According to the report, the company's annual sales were 19.375 billion US dollars (about 128 billion yuan), an increase of 3694.36% year-on-year, and the net profit was 14.459 billion US dollars (about 95.5 billion yuan), an increase of 7729.37% year-on-year.

Some media compare it with the financial reports of Tencent, Huawei and Baidu in 2021, and on profitability, Kexing Bio is about 0.42 Tencent, 0.84 Huawei, and 5 Baidu.

For the surge in revenue, the company said it was mainly due to the sale of the new crown vaccine CoronaVac.

Up to now, Kexing's new crown vaccine supply has exceeded 2.8 billion doses worldwide, of which 300 million doses have been donated domestically. In terms of scope of use, 61 countries (regional and international organizations) have been approved and 56 countries and regions have used it. According to a report by the University of Oxford, at least 24.2% of the cumulative reported vaccination against the new crown virus in the world comes from Coxing Biologics.

The sales revenue of its vaccine exports was 8.474 billion US dollars (about 55.996 billion yuan) in 2021, accounting for 43.74% of the total revenue, compared with only 28.43% in 2020. At the same time, the proportion of sales in the Chinese market in total sales decreased from 71.6% in 2020 to 56.3% in 2021.

According to the risk warning issued by Kexing Biotech, all of the company's revenue comes from the sale of vaccine products. A large part of this comes from covid-19 vaccines. The reduction in revenue from COVID-19 vaccine sales will lead to a significant decline in the company's revenue and could seriously damage the business.

On April 26, the State Food and Drug Administration officially approved the inactivated vaccine of the new coronavirus developed by Kexing Biotech based on the Aomi Kerong variant to enter clinical research.

New rules

From 1 May, guangdong will not need to approve the birth of children

From 1 May 2022, the Measures for the Administration of Birth Registration of the Guangdong Provincial Health Commission (hereinafter referred to as the Measures) were officially implemented. The "Measures" make it clear that the birth of children does not need to be approved again, and a full-caliber birth registration system is implemented.

This new regulation changes the "birth registration certificate" to a "birth registration certificate", emphasizing the neutrality and objectivity of birth registration, only as a means of population monitoring, and no longer a tool to restrict the fertility of the masses. The birth registration provided for in the "Measures" is a statutory administrative registration, and all those who give birth to children should go through birth registration.

At the same time, the registration of the subjects of birth registration has also been expanded: the provisions on the registration of unmarried births have been continued; the household registration of the registered subjects is not limited, and the household registration population of other provinces living in this province can apply for birth registration; the number of children who apply for birth registration is not limited, whether it is within three children or more, they can apply for birth registration; and the place of processing is not limited, whether it is the place of household registration or the current place of residence, can be registered.

Birth registration should generally be done before the birth of the child, and if it is not done in time, it can also be made up after the birth of the child. In terms of birth registration materials, only one type of ID card and household registration book can be provided.

More than 10 Chinese pharmaceutical companies have been listed in the Foreign Company Accountability Act by the United States this year.

According to the U.S. Securities and Exchange Commission's (SEC) Foreign Company Accountability Act (HFCAA) list, 11 Chinese pharmaceutical companies have been included this year.

On May 4, 2022, the SEC added the sixth batch of 88 companies to the HFCAA's tentative list. The deadline for submitting evidence to remove the list is 25 May. Its traditional Chinese medicine medical enterprises include: Genxi Biology, Tianyan Pharmaceutical, Tianjing Biologics, Burning Stone Medicine, Panshengzi, kexing biology.

On April 12, 2022, 12 companies entered the provisional list, including Pharmaceutical Companies including Connell Biologics and Legendary Biologics. The deadline for submitting evidence to remove the list is 3 May.

On March 8, 2022, the SEC added five companies to this list, including BeiGene, Zaiding Pharmaceutical, and Huang Pharmaceutical. The deadline for submitting evidence to remove the list is 29 March.

According to the HFCAA rules published in December 2021, the SEC has the authority to delist foreign listed companies from the exchange if they fail to file the report required by the U.S. Public Company Accounting Oversight Board for three consecutive years.

Or thrombotic risk, the U.S. Drug Administration restricts Johnson & Johnson COVID-19 vaccination

The U.S. Food and Drug Administration (FDA) announced on May 5 local time that it will limit the vaccination of Johnson & Johnson's new crown vaccine, and only allow people who cannot or do not want to receive other new crown vaccines to receive Johnson & Johnson vaccines.

The reason is that people who receive the Johnson & Johnson vaccine may have a rare, dangerous coagulation condition, known as thrombosis and thrombocytopenia syndrome (TTS). The FDA confirmed that 60 of the millions of patients vaccinated with the Johnson & Johnson vaccine developed the above symptoms, including 9 deaths.

Johnson & Johnson COVID-19 vaccine is a covid-19 vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, which requires only one dose, and was approved by the FDA on February 27, 2021, which is the third COVID-19 vaccine approved for emergency use in the United States.

According to the U.S. Centers for Disease Control and Prevention (CDC), to date, the United States has received more than 18.7 million doses of the Johnson & Johnson COVID-19 vaccine. Of the nation's populations who have been fully vaccinated, 7.7 percent of those who have been vaccinated against Johnson & Johnson against COVID-19.

In this regard, the FDA told the media that for specific groups of people, the risks of vaccinating the Johnson & Johnson COVID-19 vaccine outweigh the benefits, but for the following groups, they can still receive the Johnson & Johnson COVID-19 vaccine:

People with severe allergic reactions to Pfizer or Modena mRNA vaccines; personal concerns about mRNA vaccines, those who do not receive Johnson & Johnson COVID-19 vaccines, those who have limited access to COVID-19 vaccines.

study

After the death of the first patient with a pig heart transplant, scientists found the virus

A team of doctors at the University of Maryland said on May 5 local time that David Bennett, 57, the world's first patient to receive a pig heart transplant, died two months after the operation, and the cause of death may be related to the pig virus.

On Jan. 7 at the University of Maryland Medical Center in Baltimore, USA, David underwent surgery for a transplant pig heart. At that time, David was experiencing irreversible heart failure, and heart transplantation was the only vitality. But hearts are scarce in the United States, so his attending physician, Bartley Griffith, proposed to David to participate in a study he led: transplanting pigs' hearts into his chest. Pig hearts are about the same size as hearts and have long been seen as a potential source of human transplant organs.

About 40 days after the operation, David's condition suddenly deteriorated. Two months after the operation, David eventually passed away.

According to researchers at the University of Maryland, they found a viral DNA in the heart of a transplanted pig. The virus is called porcine cytomegalovirus, but the researchers found no signs of active infection caused by the virus. Bartley Griffiths said, "The main risk of transplanting animal organs from humans is new infections. Some viruses can lurk in transplanted animal organs without causing disease. ”

Recalling Bennett's postoperative condition, Griffith said the patient recovered fairly well after the transplant and later developed infection-like symptoms. The team of doctors tested several times to understand the cause, and took a variety of antibiotics, antiviral drugs, and immune-boosting treatments for Bennett, but the pig's heart continued to swell and eventually stopped beating.